Intelligent Bio Solutions (Nasdaq: INBS) is making its Intelligent Fingerprinting Drug Screening System more accessible to global users with a major multilingual upgrade, expanding its reach to over 4 billion people worldwide. Intelligent Bio Solutions is a B2i Digital Featured Company. View their Comprehensive B2i Digital Featured Company Profile at https://b2idigital.com/intelligent-bio-solutions. The upcoming upgrade will introduce multilingual capabilities to INBS’ portable drug screening reader, supporting languages spoken across North and South America, Europe, Asia Pacific, and the Middle East. This enhancement ensures increased usability for safety-critical industries—including construction, mining, manufacturing, transport, and logistics—where reliable, efficient workplace drug screening is essential. Harry Simeonidis, CEO of Intelligent Bio Solutions, explained the significance of the enhancement, “As we expand our global footprint, it is essential that our solutions are accessible and adaptable to meet the needs of an increasingly diverse customer base. This multilingual upgrade to our drug screening reader represents a significant step forward in our mission to deliver accessible testing solutions. Importantly, this update will open up opportunities for us to enter new international markets and customer segments, supporting revenue growth.” Read the full announcement at https://ibs.inc/2025/01/31/multilingual-intelligent-fingerprinting-drug-screening-system-upgrade/ With over 400 active accounts in 19 countries and following its FDA 510(k) submission in December 2024, the company is preparing for U.S. market entry in 2025, further positioning itself in the growing global point-of-care drug screening market. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, Intelligent Bio Solutions continues to push boundaries in non-invasive testing technologies. The company’s talented global team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli, and Peter Passaris. Intelligent Bio Solutions is a medical technology company delivering innovative, rapid, non-invasive testing solutions for employers in safety-critical industries and beyond. The company’s portable, cost-effective system provides results in under 10 minutes, detecting recent use of substances commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. For investor-related questions about INBS, please visit https://investors.ibs.inc or contact the company’s IR contact, Valter Pinto, at INBS@kcsa.com.
#IntelligentBioSolutions #INBS #WorkplaceSafety #B2iDigital #DrugScreening